Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | SVP Chief Ethics & Com Officer | May 03, 2023 | May 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date May 03, 2023 · Filed May 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,141.693 |
Ending reported balance
After 2023-05-04 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-05-03 · Exercise / conversion · Acquired 689 · Balance 4,843.693 Row 2 · 2023-05-03 · Tax withholding · Disposed 236 · Balance 4,607.693 Row 3 · 2023-05-04 · Exercise / conversion · Acquired 813 · Balance 5,420.693 Row 4 · 2023-05-04 · Tax withholding · Disposed 279 · Balance 5,141.693 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2025-05-03 | Direct | 1,378 |
Reported balance
After 2023-05-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-05-03 · Exercise / conversion · Disposed 689 · Balance 1,378 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2024-05-04 | Direct | 816 |
Reported balance
After 2023-05-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-05-04 · Exercise / conversion · Disposed 813 · Balance 816 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025.
F3: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2023 Filed May 5, 2023 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 813 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014745 · form4.xml · derivative · entry 6 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 816 Underlying: Common Stock · 813 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 279 | $118.22 | $32,983.38 |
DisclosureSEC source: 0001127602-23-014745 · form4.xml · nonDerivative · entry 4 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,141.693 Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 813 | $118.22 | $96,112.86 |
DisclosureSEC source: 0001127602-23-014745 · form4.xml · nonDerivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,420.693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2023 Filed May 5, 2023 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 689 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014745 · form4.xml · derivative · entry 5 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,378 Underlying: Common Stock · 689 shares Expires 2025-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025. Read SEC document |
| May 03, 2023 Filed May 5, 2023 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 236 | $117.89 | $27,822.04 |
DisclosureSEC source: 0001127602-23-014745 · form4.xml · nonDerivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,607.693 Read SEC document |
| May 03, 2023 Filed May 5, 2023 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 689 | $117.89 | $81,226.21 |
DisclosureSEC source: 0001127602-23-014745 · form4.xml · nonDerivative · entry 1 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,843.693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 1,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014583 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,781 Underlying: Common Stock · 1,781 shares Expires 2026-05-02 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 9,682 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014583 · form4.xml · derivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,682 Underlying: Common Stock · 9,682 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 643 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014206 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 643 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 221 | $115.47 | $25,518.87 |
DisclosureSEC source: 0001127602-23-014206 · form4.xml · nonDerivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,154.693 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 643 | $115.47 | $74,247.21 |
DisclosureSEC source: 0001127602-23-014206 · form4.xml · nonDerivative · entry 1 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,375.693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 813 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013519 · form4.xml · derivative · entry 5 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,629 Underlying: Common Stock · 813 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F5 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F6 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. F5 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 279 | $87.10 | $24,300.90 |
DisclosureSEC source: 0001127602-22-013519 · form4.xml · nonDerivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,663.781 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 813 | $87.10 | $70,812.30 |
DisclosureSEC source: 0001127602-22-013519 · form4.xml · nonDerivative · entry 1 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,942.781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 452 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013291 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 452 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 155 | $87.65 | $13,585.75 |
DisclosureSEC source: 0001127602-22-013291 · form4.xml · nonDerivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,129.781 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 452 | $87.65 | $39,617.80 |
DisclosureSEC source: 0001127602-22-013291 · form4.xml · nonDerivative · entry 1 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,284.781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 2,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013519 · form4.xml · derivative · entry 4 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,067 Underlying: Common Stock · 2,067 shares Expires 2025-05-03 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 11,650 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013519 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 11,650 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 640 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013032 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 Underlying: Common Stock · 640 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 220 | $88.69 | $19,511.80 |
DisclosureSEC source: 0001127602-22-013032 · form4.xml · nonDerivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,832.781 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 640 | $88.69 | $56,761.60 |
DisclosureSEC source: 0001127602-22-013032 · form4.xml · nonDerivative · entry 1 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,052.781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 694 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015754 · form4.xml · derivative · entry 5 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 694 shares Expires 2021-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F5 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 2,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015754 · form4.xml · derivative · entry 4 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,369 Underlying: Common Stock · 2,369 shares Expires 2024-05-04 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 18,367 | $0.00 Strike: $75.99 | $0.00 |
DisclosureSEC source: 0001127602-21-015754 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,367 Underlying: Common Stock · 18,367 shares Expires 2031-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 238 | $75.98 | $18,083.24 |
DisclosureSEC source: 0001127602-21-015754 · form4.xml · nonDerivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374.346 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 694 | $75.98 | $52,730.12 |
DisclosureSEC source: 0001127602-21-015754 · form4.xml · nonDerivative · entry 1 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,612.346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 437 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015279 · form4.xml · derivative · entry 6 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439 Underlying: Common Stock · 437 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 150 | $74.50 | $11,175.00 |
DisclosureSEC source: 0001127602-21-015279 · form4.xml · nonDerivative · entry 4 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,918.346 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 437 | $74.50 | $32,556.50 |
DisclosureSEC source: 0001127602-21-015279 · form4.xml · nonDerivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,068.346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2021 Filed May 4, 2021 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 622 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015279 · form4.xml · derivative · entry 5 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,245 Underlying: Common Stock · 622 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2021 Filed May 4, 2021 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 210 | $74.50 | $15,645.00 |
DisclosureSEC source: 0001127602-21-015279 · form4.xml · nonDerivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,631.346 Read SEC document |
| May 01, 2021 Filed May 4, 2021 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 622 | $74.50 | $46,339.00 |
DisclosureSEC source: 0001127602-21-015279 · form4.xml · nonDerivative · entry 1 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,841.346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.